Chris Klomp

Now, who are these health officials?

I think it was Chris Klomp on that one, who is the architect of the most favored nation drug pricing policy.

And, you know, they're sort of speaking out of both sides of their mouth, depending on the context, because they're simultaneously trying to reassure investors and drug makers that they're not going to lose much.

Right.

Um, you know, Rachel Winick or Jenny Schneider, um, they're amazing healthcare CEOs.

Chris Klomp, who used to be on our board, um, is an amazing healthcare CEO.

Um, and so, you know, I talk to them about some of the business stuff.

But then other CEOs, like I, I'm in CEO groups, um, and it's so helpful because what you realize when you open up about the problems, like, you know, every s- I, I feel like the sheen of so many CEOs, like everything's great, the year's never been better, like no problems at all.

What comes next if we do that? Which is the, the way it should be, but unless you ask and answer those questions before you pass the legislation or even write the legislation, you are planning to fail, and you get lot, a lot more sloganeering from both sides than you get an approach to fix the problem.

And look, on the Republican side, I talked to Chris Klomp at HHS, I talked to Dr. Oz, talked to Abe Sutton.

There are a lot of smart people who are trying to do the right thing.

Sometimes they get a little bit over themselves on technology and trying to figure out a better way there, I think, which is tough to implement, but I think generally they're trying to do the right thing.

We expect that it's going to pick up significantly through the rest of the calendar year.

There are several folks that we've been actively tracking their nominations, and they include Chris Klomp, who was nominated to be the next Deputy Secretary at HHS, and his nomination advanced out of the Senate Finance Committee.

We're also tracking the nomination of Sean Kaufman.

who has been nominated to be the next ASPR.

... improving chronic disease."

If I put myself in Chris Klomp's shoes and I hear Devoted coming to me saying, "Hey, hey, pay, pay us in the industry less," I think my first question back to them would be like, "So why are you so focused on growing in C-SNP where profitability seems to be the highest? Like, why are you not growing kind of across the board from a Medicare Advantage market perspective?" There seems to be a, a gulf between those two statements of how the plan is working, where it's prioritizing growth in profitable patients and wanting to be paid less.

Like, yes, if I could just s- siphon off the most profitable portion of the population and get paid less on that and leave everybody [chuckles] else dealing with the rest of it, I, I, I'd prob- That makes sense as a business strategy, right? It, to me, is indicative of the last part of the conversation that I put in the newsletter, which is, we have this conversation a lot these days about ideas on the fringes in healthcare that sound so great when they're just getting started.

They work really well in, like, the 1% of the population that are early adopters of that, yet as they cross the chasm into the mainstream, the, the outsized advantages get whittled away and there are questions of, of how much change really happened.